|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-6-16
|
|
pubmed:abstractText |
Bevacizumab is a monoclonal antibody targeted at vascular endothelial growth factor (VEGF) to treat advanced colorectal cancer as well as other malignancies, but the ideal time point for its administration in patients scheduled for surgery is not well defined due to serious concerns regarding possible side effects on wound healing. Therefore, we conducted an experimental study in rats to clarify this issue.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Crp protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Endothelin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyproline,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1421-9921
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
45-51
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21606651-Abdomen,
pubmed-meshheading:21606651-Angiogenesis Inhibitors,
pubmed-meshheading:21606651-Animals,
pubmed-meshheading:21606651-Antibodies, Monoclonal,
pubmed-meshheading:21606651-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21606651-Carrier Proteins,
pubmed-meshheading:21606651-Endothelin-1,
pubmed-meshheading:21606651-Hydroxyproline,
pubmed-meshheading:21606651-Injections, Intraperitoneal,
pubmed-meshheading:21606651-Male,
pubmed-meshheading:21606651-Oxidative Stress,
pubmed-meshheading:21606651-Rats,
pubmed-meshheading:21606651-Rats, Wistar,
pubmed-meshheading:21606651-Vascular Endothelial Growth Factor A,
pubmed-meshheading:21606651-Wound Healing
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Intraperitoneal administration of bevacizumab intraoperatively does not affect abdominal wound healing in rats.
|
|
pubmed:affiliation |
Second Propaedeutic Department of Surgery, Hippocration Hospital, Thessaloniki, Greece.
|
|
pubmed:publicationType |
Journal Article
|
